
Fig.1


IN THE PRESENCE OF IL-6 (0.1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)

Fig.2


IN THE PRESENCE OF IL-6 (1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)

Fig. 3


IN THE PRESENCE OF IL-6 (0.1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)

Fig.4


IN THE PRESENCE OF IL-6 (1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)


Fig.5

IN THE PRESENCE OF IL-6 (0.1 ng/ml)




CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)

Fig.6
IN THE PRESENCE OF IL-6 (1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)



hPM1 (+) MELPHALAN (+) hPM1 (+) MELPHALAN (-) hPM1 (-) MELPHALAN (+) hPM1 (-) MELPHALAN (-)






Fig.9



```
hPM1 (+) MELPHALAN (+)
hPM1 (+) MELPHALAN (-)
hPM1 (-) MELPHALAN (+)
hPM1 (-) MELPHALAN (-)
```






Fig. 12





Fig. 13

COMBINED USE OF MELPHALAN, DAY 42



BARS REPRESENT MEAN + S.E.




Fig.15

